Which intra‑articular corticosteroid and dose is appropriate for an adult joint injection?

Intra-Articular Corticosteroid Selection and Dosing for Adult Joint Injections

For adult joint injections, use triamcinolone or methylprednisolone at joint-specific doses: 20 mg for shoulder injections, 40 mg for hip and knee injections, and 10-20 mg for small/intermediate joints, with ultrasound guidance to improve accuracy and reduce procedural pain. 1

Corticosteroid Selection

No single corticosteroid has proven superiority over others for most joint injections. 1 The evidence shows:

• Triamcinolone and methylprednisolone demonstrate similar efficacy across most joint locations 2
• One exception: Triamcinolone hexacetonide showed superiority over methylprednisolone in interphalangeal finger joints in a single randomized trial 3
• The choice between agents can be based on availability and clinician familiarity given the lack of definitive comparative data 1, 3

Joint-Specific Dosing Recommendations

Large Joints

Shoulder (glenohumeral and subacromial-subdeltoid bursa):

• 20 mg triamcinolone is as effective as 40 mg 1
• Lower doses minimize systemic adverse effects while maintaining efficacy 1

Hip:

• 40 mg triamcinolone or methylprednisolone is the commonly used dose 1
• Evidence suggests 80 mg may provide superior sustained benefit at 12 weeks compared to 40 mg, particularly for stiffness and disability outcomes 4
• The 80 mg dose maintained improvement across all WOMAC domains (pain, stiffness, disability) at 12 weeks, while 40 mg only maintained stiffness improvement 4

Knee:

• 40 mg triamcinolone is as effective as 80 mg 1
• Use the lower 40 mg dose to minimize systemic effects 1

Small and Intermediate Joints

Wrist, hand, and foot joints:

• 10-20 mg methylprednisolone or triamcinolone for small joints 3
• 20-40 mg for intermediate-sized joints 3
• For wrist joints specifically, 20 mg was non-inferior to 40 mg 3

Technical Considerations

Ultrasound guidance is strongly recommended:

• Increases injection accuracy 1
• Reduces procedural pain 1
• Improves therapeutic outcomes compared to landmark-guided techniques 1

Safety Parameters and Frequency

Limit repeat injections to avoid cumulative adverse effects:

• Avoid more than 3-4 glucocorticoid injections in the same joint per year 5
• This frequency limit is based on expert consensus rather than high-quality evidence, but reflects concern for cartilage damage and other cumulative effects 5
• Conflicting evidence exists on cartilage effects: one RCT showed no deleterious effect on cartilage volume with injections every 3 months for 2 years, while another showed greater cartilage volume loss 5

Special Population Warnings

Diabetic patients require specific counseling:

• Inform patients about transient hyperglycemia risk, particularly days 1-3 post-injection 5
• Advise glucose monitoring during this period, especially in those with suboptimal control 5
• No severe adverse events (hyperosmolar hyperglycemic state or ketoacidosis) have been reported, but vigilance is warranted 5

Prosthetic joints:

• Avoid routine glucocorticoid injections in prosthetic joints 5
• Infection rate is 0.6% (1 in every 625 injections) in total knee prostheses 5
• If considered, require strict screening for prosthetic infection by orthopedic surgeons 5

Pre-surgical timing:

• Avoid injections within 3 months prior to total joint arthroplasty 5
• Injections 0-3 months before surgery showed significantly higher prosthetic infection rates (0.5-1.0%) compared to injections >3 months prior, though absolute risk increase is modest 5

Post-Injection Care

Activity modification:

• Avoid overuse of injected joints for 24 hours following injection 5
• Immobilization is discouraged - normal activity is preferred over bed rest, splinting, or bandaging 5
• Studies show 24-48 hour immobilization adds no benefit compared to normal activity 5

Expected Outcomes

Efficacy is primarily short-term:

• Intra-articular corticosteroid injections provide short-term pain relief lasting from a few weeks to a few months 1
• Most studies demonstrate positive short-term outcomes in pain and function 2
• Long-term efficacy data remains limited and mixed 5

Common Pitfalls to Avoid

• Do not use higher doses than necessary - evidence shows lower doses are often equally effective and reduce systemic adverse effects 1, 6
• Do not inject prosthetic joints routinely - infection risk necessitates careful patient selection 5
• Do not forget to counsel diabetic patients about glucose monitoring in the 72 hours post-injection 5
• Do not perform injections within 3 months of planned arthroplasty 5